LIVE INFLUENZA VACCINE. BEGINNING



Cite item

Full Text

Abstract

On December 14, 2024, Galina Ibragimovna Alexandrova, an outstanding Soviet and Russian virologist, Professor, Doctor of Medical Sciences, passed away at the 96th year of her life. A PhD student and colleague of Academician Anatoly Aleksandrovich Smorodintsev, she devoted her entire scientific life to a unique immunobiological preparation – live influenza vaccine, starting with the isolation of the A/Leningrad/134/57 (H2N2) virus in the Asian influenza pandemic of 1957 and ending with the development of a whole series of passaged and reassortant cold–adapted vaccines for adults and children. Then came fame and international recognition, the triumphal march of the live influenza vaccine across the country, with hundreds and thousands of adults and children being vaccinated against influenza every year, dozens of patents and scientific articles, and the title of Honoured Scientist of the Russian Federation… This article, describing the early stages of the development of live influenza vaccine, which determined the further directions of its progress and laid the foundation for a modern live influenza reassortant cold–adapted vaccine, is a tribute to the memory of my Teacher.

Full Text

Restricted Access

About the authors

Irina Kiseleva

Federal State Budgetary Scientific Institution «Institute of Experimental Medicine», St. Petersburg, Russia

Author for correspondence.
Email: irina.v.kiseleva@gmail.com
ORCID iD: 0000-0002-3892-9873
SPIN-code: 7857-7306
Scopus Author ID: 7102041346
ResearcherId: E–6555–2014

Professor, Ph.D., D.Sc.
Head, Laboratory of General Virology
Department of Virology
Institute of Experimental Medicine (IEM)
Email: irina.v.kiseleva@mail.ru 

Russian Federation, 12 Acad. Pavlov Street, 197022, St. Petersburg, Russia

References

  1. Harris DL, Shackell LF. The effect of vacuum dessication upon the virus of rabies with remarks upon a new method. J Am Public Health Assoc. 1911; 1(1):52–3. doi: 10.2105/ajph.1.1.52
  2. Lépine P. On the evolution of fixed strains of rabies virus. J Hyg (Lond). 1938; 38(2):180–4. doi: 10.1017/s0022172400011013
  3. Pearce JM. Louis Pasteur and rabies: a brief note. Journal of neurology, neurosurgery, and psychiatry. 2002; 73(1):82. doi: 10.1136/jnnp.73.1.82
  4. Cavaillon JM, Legout S. Louis Pasteur: Between Myth and Reality. Biomolecules. 2022; 12(4):596. doi: 10.3390/biom12040596
  5. Alexandrova GI, Klimov AI. Live influenza vaccine. SPb: Nauka; 1994. 151 p. ISBN 5-02-025988-8.
  6. Smith W, Andrewes CH, Laidlaw PP. A virus obtained from influenza patients. The Lancet. 1933; 222(5732):66–8. doi: 10.1016/S0140-6736(00)78541-2
  7. Bouvier NM. Animal models for influenza virus transmission studies: A historical perspective. Curr Opin Virol. 2015;13:101-8. doi: 10.1016/j.coviro.2015.06.002
  8. Smorodintseff AA, Drobyshevskaya AI, Shishkina. On the ætiology of the 1936 influenza epidemic in Leningrad. The Lancet. 1936; 228:1383–5.
  9. Smorodintseff AA, Tushinsky MD, Drobyshevskaya AI, et al. Investigation on volunteers infected with the influenza virus. The American Journal of the Medical Sciences. 1937;194:159–70.
  10. Francis T, Magill TP. The antibody response of human subjects vaccinated with the virus of human influenza. The Journal of experimental medicine. 1937; 65(2):251–9. doi: 10.1084/jem.65.2.251
  11. Goodpasture EW, Woodruff AM, Buddingh GJ. The cultivation of vaccine and other viruses in the chorioallantoic membrane of chick embryos. Science (New York, NY). 1931; 74(1919):371–2. doi: 10.1126/science.74.1919.371
  12. CDC Archive. 1957–1958 Pandemic (H2N2) virus. [Available from: https://archive.cdc.gov/www_cdc_gov/flu/pandemic-resources/1957-958-pandemic.html].
  13. Alexandrova GI, Smorodintsev AA. Obtaining of an additionally attenuated vaccinating cryophilic influenza strain. Rev Roum Inframicrobiol. 1965; 2:179–89.
  14. Aleksandrova GI, Mikutskaia BA, Pleshanova RA, et al. The reactive and immunogenic properties and epidemiological effectiveness of further attenuated influenza virus vaccinal strains (observed in preschool children). Vopr Virusol. 1965; 10(1):67–73. PMID: 5865829
  15. Aleksandrova G.I., Klimov A.I. Section 4.2. Methods of attenuation of influenza virus. In the book “Live influenza vaccine”. SPb: Nauka; 1994:50–69. ISBN 5-02-025988-8.
  16. Maassab HF. Adaptation and growth characteristics of influenza virus at 25 degrees c. Nature. 1967; 213(5076):612–4. doi: 10.1038/213612a0
  17. Esposito S, Montinaro V, Groppali E, et al. Live attenuated intranasal influenza vaccine. Human vaccines & immunotherapeutics. 2012; 8(1):76–80. doi: 10.4161/hv.8.1.18809
  18. Belshe R, Lee MS, Walker RE, et al. Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine. Expert review of vaccines. 2004; 3(6):643–54. doi: 10.1586/14760584.3.6.643
  19. Maassab HF, DeBorde DC. Development and characterization of cold–adapted viruses for use as live virus vaccines. Vaccine. 1985; 3(5):355–69. doi: 10.1016/0264-410x(85)90124-0
  20. Maassab HF. Plaque formation of influenza virus at 25 degrees C. Nature. 1968; 219(5154):645–6. doi: 10.1038/219645a0
  21. Burnet FM, Lind PE. A genetic approach to variation in influenza viruses; recombination of characters in influenza virus strains used in mixed infections. Journal of general microbiology. 1951; 5(1):59–66. doi: 10.1099/00221287-5-1-59
  22. Hirst GK, Gotlieb T. The experimental production of combination forms of virus. I. Occurrence of combination forms after simultaneous inoculation of the allantoic sac with two distinct strains of influenza virus. The Journal of experimental medicine. 1953; 98(1):41–52. doi: 10.1084/jem.98.1.41
  23. Kilbourne ED, Murphy JS. Genetic studies of influenza viruses. I. Viral morphology and growth capacity as exchangeable genetic traits. Rapid in ovo adaptation of early passage Asian strain isolates by combination with PR8. The Journal of experimental medicine. 1960; 111:387–406. doi: 10.1084/jem.111.3.387
  24. WHO. Recommendations for influenza vaccine composition [Available from: https://www.who.int/teams/global-influenza-programme/vaccines/who-recommendations].
  25. Aleksandrova G.I., Klimov A.I. Section 5.4. Cold–adapted live influenza B vaccine. In the book “Live influenza vaccine”. SPb: Nauka; 1994:102–109. ISBN 5-02-025988-8.
  26. Ambrose CS, Luke C, Coelingh K. Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza. Influenza and other respiratory viruses. 2008; 2(6):193–202. doi: 10.1111/j.1750-2659.2008.00056.x
  27. Desheva Iu A, Danini GV, Grigor'eva EP, et al. The investigation of the safety, genetic stability and immunogenicity of live influenza vaccine for adults in vaccination of 3-6 years old children. Vopr Virusol. 2002; 47(4):21–4. PMID: 12271720
  28. Garmashova LM, Polezhaev FI, Aleksandrova GI. Cold–adapted strain of A/Leningrad/134/47/57 (H2N2) – a special attenuation donor of live influenza vaccine for children and the isolation of its recombinants. Vopr Virusol. 1984; 29(1):28–31. PMID: 6710978
  29. Ghendon YZ, Polezhaev FI, Lisovskaya KV, et al. Recombinant cold–adapted attenuated influenza A vaccines for use in children: molecular genetic analysis of the cold–adapted donor and recombinants. Infect Immun. 1984; 44(3):730–3. doi: 10.1128/iai.44.3.730-733.1984
  30. Klimov AI, Cox NJ, Yotov WV, et al. Sequence changes in the live attenuated, cold–adapted variants of influenza A/Leningrad/134/57 (H2N2) virus. Virology. 1992; 186(2):795–7. doi: 10.1016/0042-6822(92)90050-y
  31. Alexandrova GI, Polezhaev FI, Budilovsky GN, et al. Recombinant cold–adapted attenuated influenza A vaccines for use in children: reactogenicity and antigenic activity of cold–adapted recombinants and analysis of isolates from the vaccinees. Infect Immun. 1984; 44(3):734–9. doi: 10.1128/iai.44.3.734-739.1984
  32. Alexandrova GI, Budilovsky GN, Koval TA, et al. Study of live recombinant cold-adapted influenza bivalent vaccine of type A for use in children: an epidemiological control trial. Vaccine. 1986;4(2):114-8. doi: 10.1016/0264-410x(86)90049-6
  33. Shcherbik S, Pearce N, Kiseleva I, et al. Implementation of new approaches for generating conventional reassortants for live attenuated influenza vaccine based on Russian master donor viruses. J Virol Methods. 2016; 227:33–9. doi: 10.1016/j.jviromet.2015.10.009
  34. Jin H, Subbarao K. Live attenuated influenza vaccine. Current topics in microbiology and immunology. 2015; 386:181–204. doi: 10.1007/82_2014_410
  35. Friede M, Palkonyay L, Alfonso C, et al. WHO initiative to increase global and equitable access to influenza vaccine in the event of a pandemic: supporting developing country production capacity through technology transfer. Vaccine. 2011; 29 Suppl 1:A2–7. doi: 10.1016/j.vaccine.2011.02.079
  36. Dhere R, Yeolekar L, Kulkarni P, et al. A pandemic influenza vaccine in India: from strain to sale within 12 months. Vaccine. 2011; 29 Suppl 1:A16–21. doi: 10.1016/j.vaccine.2011.04.119
  37. Changchun BCHT Biotechnology Co. Influenza Vaccine, Live, Nasal, Freeze–dried. 2020 [Available from: https://www.cphi-online.com/influenza-accine-live-nasal-reeze-ried-prod1296007.html]
  38. Shen Z, Bowen RA, Ge P, et al. Evaluation of a candidate live attenuated influenza vaccine prepared in Changchun BCHT (China) for safety and efficacy in ferrets. Vaccine. 2016; 34(48):5953–8. doi: 10.1016/j.vaccine.2016.09.059

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 74760 от 29.12.2018 г.